Since CD30 is expressed on 38% of cases of T-ALL and is up-regulated during high-dose chemotherapy [130], anti-CD30-based immunotherapy could be a promising strategy for T-ALL patients. This evidence concerns the gene TNFRSF8 and acute lymphoblastic leukemia.